The use of T-cell replete grafts from HLA-haploidentical (haplo) donors, with post-transplant cyclophosphamide (PTCy) for acute GvHD (aGvHD) prophylaxis, is efficacious in patients who do not have a matched sibling or timely access to a matched unrelated donor. 1, 2 Early studies investigating haplo hematopoietic cell transplantation (HCT) with PTCy used bone marrow grafts to help mitigate the risk of GvHD; however, disease relapse remains the major cause of transplant failure. 2, 3 At Washington University School of Medicine, we have almost exclusively used G-CSF mobilized (PBSC) grafts for haplo-HCT. The goal of this study is to present our experience utilizing this haplo-HCT platform to treat various hematologic malignancies as a follow-up to previously published preliminary data. 4 We retrospectively evaluated 102 adult patients who underwent haplo-HCT for various hematologic malignancies at Washington University Medical Center from July 2009 through May 2015. This study was approved by the Institutional Review Board of Washington University School of Medicine in Saint Louis. Patient outcomes were monitored by retrospective chart review through the end of June 2016 with a median follow-up of 19.5 months (range 6.8-63.1 months) for survivors. This was a high-risk patient population with 56 patients having active disease at the time of their transplant, 42 had high risk cytogenetics, 24 had a previous allo-HCT and only 18 patients were transplanted in their first CR. Patient, disease and transplant characteristics are listed in Table 1 .
The indications for haplo-HCT were a lack of a readily available HLA-matched related or unrelated donor in patients otherwise needing allo-HCT. All haplo grafts were collected from G-CSFmobilized PBSC of haploidentical donors. After a myeloablative or reduced intensity condition (RIC) regimen, patients were infused with a target of 5.0 × 10 6 CD34+ cells/kg. For GvHD prophylaxis, in addition to PTCy 50 mg/kg on days +3 and +4, all patients received tacrolimus from day +5 to 180 and mycophenolate mofetil from day +5 to 35 as previously described. 5 Patients were started on daily G-CSF 5 mcg/kg on day +5 until ANC recovery.
After a median follow-up of 19.5 months, 41 patients remained alive. Of the 62 patients that expired, 33 died from disease relapse, 10 died from infection, 10 died from aGvHD and 9 died from other causes. The 1-year overall survival (OS) and event free survival (EFS) for this cohort were 50.8% (95% CI: 42.0-61.5%) and 42.0% (33.4-52.8%), respectively. One-year OS and EFS for the subset of patients in remission at the time of haplo-HCT was 56.8% (43.9-73.5%) and 47.7% (35.0-65.0%) (Figure 1 ). Univariate analysis showed a worse OS with haplo-HCT using a CMV+ donor into a CMV − recipient (HR 2.4, 95% CI: 1. Forty patients had disease relapse at a median of 5.0 months post-transplant (range 0.8-37.0 months). The 1-year cumulative incidence of disease relapse was 33.5% (24.1-42.9). For patients in remission at transplant, the 1-year cumulative incidence of relapse was 20.5% (8.1-32.8%). Univariate analysis of disease relapse showed patients in remission at time of haplo-HCT had a reduced risk of relapse (HR 0.39, 0.19-0.78) and that those with very high-risk DRI had an increased risk of relapse (HR 4.4, 1.0-10.1). Univariate analysis of relapse did not show any other associations with patient, disease or transplant characteristics.
ANC and platelet count recoveries occurred after a median of 17 days (range 11-78) and 27 days (range 8-214). All but 10 patients had ANC recovery by day 28, of which 5 recovered after a median of 32 days (range 29-42), 2 required a second donor cell infusion at a median of day 47, 2 patients had disease relapse at days 28 and 40, and 1 died of disease relapse at day 62 without count recovery. Of the 95 patients alive at posttransplant day 30, testing of short tandem repeats in blood or bone marrow showed 495% donor chimerism occurred in 83 patients, mixed chimerism was achieved in 10 patients, and only 1 patient had o5% chimerism, due to persistent disease at day 28. Of the 10 patients with mixed chimerism, 4 died from disease relapse, 2 from infection and 1 from aGvHD.
The cumulative incidence of grades II-IV and III-IV aGvHD at 6 months were 38.2% (28.2-48.2%) and 17.1% (95% CI: 8.9-25.4%). The median time to developing aGvHD was 35 days (range 16-172). There were 7 cases of grades III-IV aGvHD of the skin, 10 cases of GI and 2 cases of liver GvHD. The cumulative incidence of all grades and severe chronic GvHD (cGvHD) at 1-year was 33.6% (24.0-43.2%) and 2.9% (0-6.4%), respectively. The median time to developing cGvHD was 191 days (range 80-931). cGvHD was preceded by aGvHD in 30 of 38 cases with 22 cases being grades II-IV and 9 cases being grades III-IV aGvHD. There was no significant correlation between having moderate or severe aGvHD and developing cGvHD (P = 0.31, P = 0.66). Developing severe cGvHD was associated with having moderate (P = 0.015) or severe (P = 0.10) aGvHD. Univariate analysis of aGvHD and cGvHD did not show any other association with patient, disease or transplant characteristics.
Universal screening for donor-specific antibodies (DSA) was instituted after October 2014 so only 83 patients in the cohort were screened for DSA. Of these, 14 patients (17%) were transplanted with detectable DSA. The presence of DSA was associated with worse OS (HR 2.3, 1.2-4.6) and EFS (HR 2.1, 1.1-4.3). Three of the 14 patients underwent desensitization with plasmapheresis as previously described. 6 Of these three, one died of an intracranial hemorrhage at day 11 and two remain alive at 616 and 625 days post transplant.
Because HLA mismatch, myeloablative conditioning and peripheral blood-derived grafts are all factors that confer increased risk of GvHD, bone marrow-derived grafts are most commonly used in haplo-HCT to help mitigate this risk. 7 The initial Hopkins regimen used RIC and bone marrow-derived grafts and resulted in low rates of GvHD, NRM and promising OS. 1 However, disease relapse remains the major cause of transplant failure and PBSC grafts are now widely used for other types of adult HCT as they may be associated with reduced rates of relapse and better OS. 8 Despite the high-risk population in this study, we found that outcomes were comparable to prior studies of haplo-HCT with PTCy using bone marrow grafts and PBSC grafts. 9, 10 In our study, the 6-month cumulative incidence of grades II-IV aGvHD was 38%, which is similar to rates previously described using PBSC HCT and PTCy that have ranged from 30 to 61%. 5, 9, 11, 12 These rates of aGvHD were also not considerably different than haplo-HCT with bone marrow grafts, for which rates of aGvHD have been reported between 27 and 43%. [1] [2] [3] 5, 13, 14 Furthermore, the low incidence of severe cGvHD is particularly encouraging since PBSC grafts have been associated with a higher incidence of cGvHD. 8 The 1-year OS in this patient cohort was 51%, limited by disease relapse and TRM as the leading causes of death. The 1-year TRM was high at 25%, but similar to previously reported data with similarly high-risk patients undergoing PBSC haplo-HCT. 11, 12 Even with 54% of the cohort having active disease at the time of haplo-HCT, the 1-year relapse rate was 34%, comparing favorably to prior studies using haplo-HCT with PTCy with 1-year relapse rates between 28 and 51%. 1, [9] [10] [11] 13, 14 On multivariate analysis, age 440 was associated with worse OS and having a very high DRI with worse EFS. Patients in remission at the time of haplo-HCT had a much lower 2-year cumulative relapse rate at 20% versus 43% for the entire patient cohort. Being in remission was associated with reduced risk of relapse but not OS on univariate analysis. Although this may be due to relatively short follow-up, previous studies with matched sibling and matched unrelated donor allo-HCT showed significant differences in OS and EFS between patients transplanted in remission and those with either minimal residual disease or active disease. 15 The OS and EFS of our haplo-HCT patients transplanted with active disease are quite encouraging, suggesting this haplo-HCT platform may be the best alternative for patients undergoing allo-HCT with minimal residual disease or active disease.
This study was subject to the limitations associated with retrospective analyses with patients receiving a variety of conditioning regimens. Furthermore, since haplo-HCT was not considered a first-line treatment at our institution, our analysis is based on an extremely high-risk cohort and probably underestimates the efficacy of PBSC haplo-HCT in the general transplant population. Although our study examines what is, to our knowledge, the largest cohort of PBSC haplo-HCT patients reported in the literature, our analyses are still substantially limited by sample size and relatively short median follow-up. However, our study has several strengths. Our patients were all treated at the same transplant center and were managed with similar prophylactic and supportive care measures and we are able to minimize the impact of variations in institutional practice as a confounder in our analysis.
In conclusion, our results suggest using PBSC grafts for haplo-HCT with PTCy is associated with excellent rates of donor engraftment and acceptable rates of GvHD, relapse, OS and EFS given the high-risk patient population. Furthermore, this transplant platform appears efficacious in high-risk individuals with refractory disease or those who have failed prior allogeneic transplantation.
